Parkinson's Disease
From the Journals
Driving ability of Parkinson’s patients can decline quickly
Findings suggest that health care providers should routinely ask about driving status and make referrals for testing if necessary.
Conference Coverage
IncobotulinumtoxinA May Benefit Patients With Sialorrhea
VANCOUVER—IncobotulinumtoxinA may help treat sialorrhea in patients with Parkinson’s disease or other neurologic conditions, according to a study...
From the Journals
Caffeine offers no perks for Parkinson’s patients
The findings from a 6-month, double-blind, multicenter, placebo-controlled trial contradict those from an earlier 6-week pilot trial.
Expert Commentary
Commentary—A Credible Case for Neuroprotection
To date, efforts to translate exciting laboratory findings into clinical trials for Parkinson’s disease have not met with much success. However,...
Literature Review
Exenatide Aids Motor Function in Parkinson’s Disease
Exenatide improves motor function in patients with Parkinson’s disease, according to research published online ahead of print August 3 in Lancet....
From the Journals
Early cognitive impairment associated with later Parkinson’s disease
Patients with parkinsonism showed early evidence of mild cognitive decline.
From the Journals
Poor smell predicts 6-year risk of Parkinson’s
Is poor smell a better predictor of Parkinson’s disease than previously thought?
From the Journals
Exenatide improved motor function in Parkinson’s patients with off-medication symptoms
There were no other significant differences between exenatide and placebo besides off-medication motor symptoms.
Conference Coverage
Patients With Dementia With Lewy Bodies May Have Unfavorable Hospital Outcomes
VANCOUVER—Patients with dementia with Lewy bodies have a high rate of hospitalization for hallucinations or confusion, falls, and infection,...
Conference Coverage
Standard Assessments May Miss Psychotic Symptoms in Patients With Parkinson’s Disease
VANCOUVER—Standard clinical assessments of Parkinson’s disease psychosis may miss more than half of psychotic symptoms, according to research...
FDA/CDC
Extended-release amantadine approved for treatment of dyskinesia in Parkinson’s
This is the first FDA approval for a drug to treat levodopa therapy-related dyskinesia in patients with Parkinson’s disease.